The Food and Drug Administration last week updated 2017 draft guidance to clarify the categories of clinical and decision support software subject to FDA oversight under the 21st Century Cures Act based on risk, and released final guidance on the types of software no longer considered medical devices under the Act’s amended definition of device. “We’re making clear that certain digital health technologies — such as mobile apps that are intended only for maintaining or encouraging a healthy lifestyle — generally fall outside the scope of the FDA’s regulation,” said Principal Deputy Commissioner Abernethy, M.D. “Such technologies tend to pose a low risk to patients, but can provide great value to consumers and the health care system.”

Related News Articles

Headline
AHA submitted a statement to the House Energy and Commerce Subcommittee on Health for a hearing April 30 on proposed legislation to address Medicaid access and…
Headline
Three retiring members of Congress — Brad Wenstrup, R-Ohio, Larry Bucshon, R-Ind., and Dan Kildee, D-Mich. — engaged in a genial conversation that covered the…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
Stacey Hughes, AHA’s executive vice president for government relations and public policy, discussed key messages that hospital and health system leaders should…
Perspective
While Congress passed legislation last month to fund the federal government through September, it’s looking like there will be very few other pieces of…
Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…